Boston Scientific (BSX)VA awarded $880K

$880K

committed so far

Signed

Oct 1, 2026

Updated

Oct 1, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 23, 2025Federal contract · $493K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $493K obligated to date
2. Jul 31, 2026InsiderDirector purchased ~$227K of BSX shares in the open market
3. Aug 3, 2026Insider · 2 peopleInsiders: 2 purchases (~$9.1M)
4. Aug 4, 2026FDAFDA device clearance: Navigator™ Flex Ureteral Access Sheath Set
5. Aug 4, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$6.8K of BSX shares in the open market
6. Aug 5, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$100K of BSX shares in the open market
7. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS US, Model Number 7260, All Versions (Current 7.8)
8. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS ANZ, Model Number 7248, All Versions (Current 7.7)
9. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS EU, Model Number 7246, All Versions (Current 7.7)
10. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 3.1%
11. Aug 12, 2026FDAFDA device clearance: EluPro Antibiotic-Eluting BioEnvelope
12. Aug 18, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
13. Aug 21, 2026FDAFDA device clearance: AVVIGO™+ Multi-Modality Guidance System
14. Aug 24, 2026FDARecall: Imager II Angiographic Catheters M001314001 IMAGER II/5/ST/65/038 BX5; M001314011 IMAGER II/5/ST/100/038 BX5; M001314021 IMAGER II/5/ST/65/035 BX 5; M001314031…
15. Aug 25, 2026Insider · 13 days before an 8-KDirector purchased ~$100K of BSX shares in the open market
16. Aug 26, 2026FDAFDA device clearance: LithoVue Elite Digital Flexible Ureteroscope System
17. Aug 31, 2026CongressDisclosed sale of BSX — reported range $15,001 - $50,000
18. Sep 3, 2026FDAFDA device clearance: Rezum System
19. Sep 3, 2026Congress · 1 personMembers of Congress: 3 sales
20. Sep 4, 2026CongressDisclosed partial sale of BSX — reported range $50,001 - $100,000
21. Sep 7, 2026Company filing · Form 8-K · Cyber incidentReported a cybersecurity incident“As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “ Company ”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global disruption to the Company’s operations.”
22. Sep 9, 2026CongressDisclosed sale of BSX — reported range $50,001 - $100,000
23. Sep 11, 2026FDAFDA device clearance: SpaceOAR Flex™ System
24. Sep 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.”
25. Oct 1, 2026 · this disclosureFederal contract · $880K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $880K obligated to date

What came next

1. Oct 1, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.”
2. Oct 1, 2026Federal contract · $465K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $465K obligated to date
3. Oct 1, 2026Federal contract · $524K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $524K obligated to date
4. Oct 1, 2026Federal contract · $832K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $832K obligated to date
5. Oct 1, 2026Federal contract · $1.0M obligatedDepartment of Veterans Affairs awarded Boston Scientific: $1.05M obligated to date

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Boston Scientific

• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• House Clerk periodic transaction reportSep 25, 2026
• House Clerk periodic transaction reportSep 25, 2026

Everything OQRO holds on this company is on its BSX page.